APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neurocognitive Assessment and Rehabilitation

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Neurocognitive Assessment and Rehabilitation Market Outlook and Growth Opportunities 2026

2 May 2026195 pages

Choose your research edition.

Industry ResearchNeurocognitive Assessment and Rehabilitation Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Neurocognitive Assessment and Rehabilitation Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Neurocognitive Assessment and Rehabilitation Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neurocognitive Assessment and Rehabilitation Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Neurocognitive Assessment and Rehabilitation Market Analysis and Forecast 2026-2032220 pages · $4,950 USD

Market perspective

The global Neurocognitive Assessment and Rehabilitation market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Neurocognitive Assessment and Rehabilitation is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neurocognitive Assessment and Rehabilitation is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neurocognitive Assessment and Rehabilitation is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Neurocognitive Assessment and Rehabilitation market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Neurocognitive Assessment and Rehabilitation market include Cambridge Cognition Holdings plc, Cognifit, Inc., Cogstate Ltd., Lumos Labs, Inc. (Lumosity), CNS Vital Signs, LLC, Posit Science Corporation, BrainCheck, Inc., Constant Therapy Health and NeuronUP SL, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Neurocognitive Assessment and Rehabilitation market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neurocognitive Assessment and Rehabilitation and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neurocognitive Assessment and Rehabilitation revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Neurocognitive Assessment and Rehabilitation market.

Neurocognitive Assessment and Rehabilitation Segment by Company

Cambridge Cognition Holdings plc

Cognifit, Inc.

Cogstate Ltd.

Lumos Labs, Inc. (Lumosity)

CNS Vital Signs, LLC

Posit Science Corporation

BrainCheck, Inc.

Constant Therapy Health

NeuronUP SL

SCHUHFRIED GmbH

Neurocognitive Assessment and Rehabilitation Segment by Type

Neurorehabilitation Therapy

Neurocognitive Assessment Testing

Neurocognitive Assessment and Rehabilitation Segment by Application

Rehab Centers

Hospital & Clinics

Homecare Settings

Physiotherapy Centers

Neurocognitive Assessment and Rehabilitation Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Neurocognitive Assessment and Rehabilitation status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Neurocognitive Assessment and Rehabilitation key companies, revenue, market share, and recent developments.

3. To split the Neurocognitive Assessment and Rehabilitation breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Neurocognitive Assessment and Rehabilitation market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Neurocognitive Assessment and Rehabilitation significant trends, drivers, influence factors in global and regions.

6. To analyze Neurocognitive Assessment and Rehabilitation competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurocognitive Assessment and Rehabilitation market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neurocognitive Assessment and Rehabilitation and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurocognitive Assessment and Rehabilitation.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neurocognitive Assessment and Rehabilitation industry.

Chapter 3: Detailed analysis of Neurocognitive Assessment and Rehabilitation company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Neurocognitive Assessment and Rehabilitation in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Neurocognitive Assessment and Rehabilitation in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Neurocognitive Assessment and Rehabilitation Industry Trends Table 2. Neurocognitive Assessment and Rehabilitation Industry Drivers Table 3. Neurocognitive Assessment and Rehabilitation Industry Opportunities and Challenges Table 4. Neurocognitive Assessment and Rehabilitation Industry Restraints Table 5. Global Neurocognitive Assessment and Rehabilitation Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Neurocognitive Assessment and Rehabilitation Revenue Share by Company (2021-2026) Table 7. Global Neurocognitive Assessment and Rehabilitation Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Neurocognitive Assessment and Rehabilitation Key Company Manufacturing Base & Headquarters Table 9. Global Neurocognitive Assessment and Rehabilitation Company, Product Type & Application Table 10. Global Neurocognitive Assessment and Rehabilitation Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Neurocognitive Assessment and Rehabilitation by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Neurorehabilitation Therapy Table 15. Significant Companies of Neurocognitive Assessment Testing Table 16. Global Neurocognitive Assessment and Rehabilitation Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Neurocognitive Assessment and Rehabilitation Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Neurocognitive Assessment and Rehabilitation Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Neurocognitive Assessment and Rehabilitation Sales Value Share by Type (2021-2026) Table 20. Global Neurocognitive Assessment and Rehabilitation Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Rehab Centers Table 22. Significant Companies of Hospital & Clinics Table 23. Significant Companies of Homecare Settings Table 24. Significant Companies of Physiotherapy Centers Table 25. Global Neurocognitive Assessment and Rehabilitation Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Neurocognitive Assessment and Rehabilitation Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Neurocognitive Assessment and Rehabilitation Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Neurocognitive Assessment and Rehabilitation Sales Value Share by Application (2021-2026) Table 29. Global Neurocognitive Assessment and Rehabilitation Sales Value Share by Application (2027-2032) Table 30. Global Neurocognitive Assessment and Rehabilitation Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Neurocognitive Assessment and Rehabilitation Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Neurocognitive Assessment and Rehabilitation Sales Value Share by Region (2021-2026) Table 33. Global Neurocognitive Assessment and Rehabilitation Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Neurocognitive Assessment and Rehabilitation Sales Value Share by Region (2027-2032) Table 35. Global Neurocognitive Assessment and Rehabilitation Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Neurocognitive Assessment and Rehabilitation Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Neurocognitive Assessment and Rehabilitation Sales Value Market Share by Country (2021-2026) Table 38. Global Neurocognitive Assessment and Rehabilitation Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Neurocognitive Assessment and Rehabilitation Sales Value Market Share by Country (2027-2032) Table 40. Cambridge Cognition Holdings plc Company Information Table 41. Cambridge Cognition Holdings plc Business Overview Table 42. Cambridge Cognition Holdings plc Neurocognitive Assessment and Rehabilitation Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Cambridge Cognition Holdings plc Neurocognitive Assessment and Rehabilitation Product Portfolio Table 44. Cambridge Cognition Holdings plc Recent Development Table 45. Cognifit, Inc. Company Information Table 46. Cognifit, Inc. Business Overview Table 47. Cognifit, Inc. Neurocognitive Assessment and Rehabilitation Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Cognifit, Inc. Neurocognitive Assessment and Rehabilitation Product Portfolio Table 49. Cognifit, Inc. Recent Development Table 50. Cogstate Ltd. Company Information Table 51. Cogstate Ltd. Business Overview Table 52. Cogstate Ltd. Neurocognitive Assessment and Rehabilitation Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Cogstate Ltd. Neurocognitive Assessment and Rehabilitation Product Portfolio Table 54. Cogstate Ltd. Recent Development Table 55. Lumos Labs, Inc. (Lumosity) Company Information Table 56. Lumos Labs, Inc. (Lumosity) Business Overview Table 57. Lumos Labs, Inc. (Lumosity) Neurocognitive Assessment and Rehabilitation Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Lumos Labs, Inc. (Lumosity) Neurocognitive Assessment and Rehabilitation Product Portfolio Table 59. Lumos Labs, Inc. (Lumosity) Recent Development Table 60. CNS Vital Signs, LLC Company Information Table 61. CNS Vital Signs, LLC Business Overview Table 62. CNS Vital Signs, LLC Neurocognitive Assessment and Rehabilitation Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. CNS Vital Signs, LLC Neurocognitive Assessment and Rehabilitation Product Portfolio Table 64. CNS Vital Signs, LLC Recent Development Table 65. Posit Science Corporation Company Information Table 66. Posit Science Corporation Business Overview Table 67. Posit Science Corporation Neurocognitive Assessment and Rehabilitation Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Posit Science Corporation Neurocognitive Assessment and Rehabilitation Product Portfolio Table 69. Posit Science Corporation Recent Development Table 70. BrainCheck, Inc. Company Information Table 71. BrainCheck, Inc. Business Overview Table 72. BrainCheck, Inc. Neurocognitive Assessment and Rehabilitation Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. BrainCheck, Inc. Neurocognitive Assessment and Rehabilitation Product Portfolio Table 74. BrainCheck, Inc. Recent Development Table 75. Constant Therapy Health Company Information Table 76. Constant Therapy Health Business Overview Table 77. Constant Therapy Health Neurocognitive Assessment and Rehabilitation Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Constant Therapy Health Neurocognitive Assessment and Rehabilitation Product Portfolio Table 79. Constant Therapy Health Recent Development Table 80. NeuronUP SL Company Information Table 81. NeuronUP SL Business Overview Table 82. NeuronUP SL Neurocognitive Assessment and Rehabilitation Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. NeuronUP SL Neurocognitive Assessment and Rehabilitation Product Portfolio Table 84. NeuronUP SL Recent Development Table 85. SCHUHFRIED GmbH Company Information Table 86. SCHUHFRIED GmbH Business Overview Table 87. SCHUHFRIED GmbH Neurocognitive Assessment and Rehabilitation Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. SCHUHFRIED GmbH Neurocognitive Assessment and Rehabilitation Product Portfolio Table 89. SCHUHFRIED GmbH Recent Development Table 90. Research Programs/Design for This Report Table 91. Authors List of This Report Table 92. Secondary Sources Table 93. Primary Sources List of Figures Figure 1. Neurocognitive Assessment and Rehabilitation Product Image Figure 2. Global Neurocognitive Assessment and Rehabilitation Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neurocognitive Assessment and Rehabilitation Market Size (2021-2032) & (US$ Million) Figure 4. Global Neurocognitive Assessment and Rehabilitation Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Neurorehabilitation Therapy Image Figure 8. Neurocognitive Assessment Testing Image Figure 9. Global Neurocognitive Assessment and Rehabilitation Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Neurocognitive Assessment and Rehabilitation Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Neurocognitive Assessment and Rehabilitation Sales Value Share by Type (2021-2032) Figure 12. Rehab Centers Image Figure 13. Hospital & Clinics Image Figure 14. Homecare Settings Image Figure 15. Physiotherapy Centers Image Figure 16. Global Neurocognitive Assessment and Rehabilitation Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Neurocognitive Assessment and Rehabilitation Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Neurocognitive Assessment and Rehabilitation Sales Value Share by Application (2021-2032) Figure 19. Global Neurocognitive Assessment and Rehabilitation Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Neurocognitive Assessment and Rehabilitation Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Neurocognitive Assessment and Rehabilitation Sales Value (2021-2032) & (US$ Million) Figure 22. North America Neurocognitive Assessment and Rehabilitation Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Neurocognitive Assessment and Rehabilitation Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Neurocognitive Assessment and Rehabilitation Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Neurocognitive Assessment and Rehabilitation Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Neurocognitive Assessment and Rehabilitation Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Neurocognitive Assessment and Rehabilitation Sales Value (2021-2032) & (US$ Million) Figure 28. South America Neurocognitive Assessment and Rehabilitation Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Neurocognitive Assessment and Rehabilitation Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Neurocognitive Assessment and Rehabilitation Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Neurorehabilitation Therapy
  • Neurocognitive Assessment Testing
Applications
  • Rehab Centers
  • Hospital & Clinics
  • Homecare Settings
  • Physiotherapy Centers
Companies covered
  • Cambridge Cognition Holdings plc
  • Cognifit, Inc.
  • Cogstate Ltd.
  • Lumos Labs, Inc. (Lumosity)
  • CNS Vital Signs, LLC
  • Posit Science Corporation
  • BrainCheck, Inc.
  • Constant Therapy Health
  • NeuronUP SL
  • SCHUHFRIED GmbH

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Neurocognitive Assessment and Rehabilitation Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Neurocognitive Assessment and Rehabilitation Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Neurocognitive Assessment and Rehabilitation Market Dynamics
  1. 2.1 Neurocognitive Assessment and Rehabilitation Industry Trends
  2. 2.2 Neurocognitive Assessment and Rehabilitation Industry Drivers
  3. 2.3 Neurocognitive Assessment and Rehabilitation Industry Opportunities and Challenges
  4. 2.4 Neurocognitive Assessment and Rehabilitation Industry Restraints
3 Neurocognitive Assessment and Rehabilitation Market by Company
  1. 3.1 Global Neurocognitive Assessment and Rehabilitation Company Revenue Ranking in 2025
  2. 3.2 Global Neurocognitive Assessment and Rehabilitation Revenue by Company (2021-2026)
  3. 3.3 Global Neurocognitive Assessment and Rehabilitation Company Ranking (2024-2026)
  4. 3.4 Global Neurocognitive Assessment and Rehabilitation Company Manufacturing Base and Headquarters
  5. 3.5 Global Neurocognitive Assessment and Rehabilitation Company Product Type and Application
  6. 3.6 Global Neurocognitive Assessment and Rehabilitation Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Neurocognitive Assessment and Rehabilitation Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Neurocognitive Assessment and Rehabilitation Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Neurocognitive Assessment and Rehabilitation Market by Type
  1. 4.1 Neurocognitive Assessment and Rehabilitation Type Introduction
  2. 4.1.1 Neurorehabilitation Therapy
  3. 4.1.2 Neurocognitive Assessment Testing
  4. 4.2 Global Neurocognitive Assessment and Rehabilitation Sales Value by Type
  5. 4.2.1 Global Neurocognitive Assessment and Rehabilitation Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Neurocognitive Assessment and Rehabilitation Sales Value by Type (2021-2032)
  7. 4.2.3 Global Neurocognitive Assessment and Rehabilitation Sales Value Share by Type (2021-2032)
5 Neurocognitive Assessment and Rehabilitation Market by Application
  1. 5.1 Neurocognitive Assessment and Rehabilitation Application Introduction
  2. 5.1.1 Rehab Centers
  3. 5.1.2 Hospital & Clinics
  4. 5.1.3 Homecare Settings
  5. 5.1.4 Physiotherapy Centers
  6. 5.2 Global Neurocognitive Assessment and Rehabilitation Sales Value by Application
  7. 5.2.1 Global Neurocognitive Assessment and Rehabilitation Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Neurocognitive Assessment and Rehabilitation Sales Value by Application (2021-2032)
  9. 5.2.3 Global Neurocognitive Assessment and Rehabilitation Sales Value Share by Application (2021-2032)
6 Neurocognitive Assessment and Rehabilitation Regional Value Analysis
  1. 6.1 Global Neurocognitive Assessment and Rehabilitation Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neurocognitive Assessment and Rehabilitation Sales Value by Region (2021-2032)
  3. 6.2.1 Global Neurocognitive Assessment and Rehabilitation Sales Value by Region: 2021-2026
  4. 6.2.2 Global Neurocognitive Assessment and Rehabilitation Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Neurocognitive Assessment and Rehabilitation Sales Value (2021-2032)
  7. 6.3.2 North America Neurocognitive Assessment and Rehabilitation Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Neurocognitive Assessment and Rehabilitation Sales Value (2021-2032)
  10. 6.4.2 Europe Neurocognitive Assessment and Rehabilitation Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Neurocognitive Assessment and Rehabilitation Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Neurocognitive Assessment and Rehabilitation Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Neurocognitive Assessment and Rehabilitation Sales Value (2021-2032)
  16. 6.6.2 South America Neurocognitive Assessment and Rehabilitation Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Neurocognitive Assessment and Rehabilitation Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Neurocognitive Assessment and Rehabilitation Sales Value Share by Country, 2025 VS 2032
7 Neurocognitive Assessment and Rehabilitation Country-level Value Analysis
  1. 7.1 Global Neurocognitive Assessment and Rehabilitation Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Neurocognitive Assessment and Rehabilitation Sales Value by Country (2021-2032)
  3. 7.2.1 Global Neurocognitive Assessment and Rehabilitation Sales Value by Country (2021-2026)
  4. 7.2.2 Global Neurocognitive Assessment and Rehabilitation Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Neurocognitive Assessment and Rehabilitation Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Neurocognitive Assessment and Rehabilitation Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Neurocognitive Assessment and Rehabilitation Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Cambridge Cognition Holdings plc
  2. 8.1.1 Cambridge Cognition Holdings plc Company Information
  3. 8.1.2 Cambridge Cognition Holdings plc Business Overview
  4. 8.1.3 Cambridge Cognition Holdings plc Neurocognitive Assessment and Rehabilitation Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Cambridge Cognition Holdings plc Neurocognitive Assessment and Rehabilitation Product Portfolio
  6. 8.1.5 Cambridge Cognition Holdings plc Recent Developments
  7. 8.2 Cognifit, Inc.
  8. 8.2.1 Cognifit, Inc. Company Information
  9. 8.2.2 Cognifit, Inc. Business Overview
  10. 8.2.3 Cognifit, Inc. Neurocognitive Assessment and Rehabilitation Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Cognifit, Inc. Neurocognitive Assessment and Rehabilitation Product Portfolio
  12. 8.2.5 Cognifit, Inc. Recent Developments
  13. 8.3 Cogstate Ltd.
  14. 8.3.1 Cogstate Ltd. Company Information
  15. 8.3.2 Cogstate Ltd. Business Overview
  16. 8.3.3 Cogstate Ltd. Neurocognitive Assessment and Rehabilitation Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Cogstate Ltd. Neurocognitive Assessment and Rehabilitation Product Portfolio
  18. 8.3.5 Cogstate Ltd. Recent Developments
  19. 8.4 Lumos Labs, Inc. (Lumosity)
  20. 8.4.1 Lumos Labs, Inc. (Lumosity) Company Information
  21. 8.4.2 Lumos Labs, Inc. (Lumosity) Business Overview
  22. 8.4.3 Lumos Labs, Inc. (Lumosity) Neurocognitive Assessment and Rehabilitation Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Lumos Labs, Inc. (Lumosity) Neurocognitive Assessment and Rehabilitation Product Portfolio
  24. 8.4.5 Lumos Labs, Inc. (Lumosity) Recent Developments
  25. 8.5 CNS Vital Signs, LLC
  26. 8.5.1 CNS Vital Signs, LLC Company Information
  27. 8.5.2 CNS Vital Signs, LLC Business Overview
  28. 8.5.3 CNS Vital Signs, LLC Neurocognitive Assessment and Rehabilitation Revenue and Gross Margin (2021-2026)
  29. 8.5.4 CNS Vital Signs, LLC Neurocognitive Assessment and Rehabilitation Product Portfolio
  30. 8.5.5 CNS Vital Signs, LLC Recent Developments
  31. 8.6 Posit Science Corporation
  32. 8.6.1 Posit Science Corporation Company Information
  33. 8.6.2 Posit Science Corporation Business Overview
  34. 8.6.3 Posit Science Corporation Neurocognitive Assessment and Rehabilitation Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Posit Science Corporation Neurocognitive Assessment and Rehabilitation Product Portfolio
  36. 8.6.5 Posit Science Corporation Recent Developments
  37. 8.7 BrainCheck, Inc.
  38. 8.7.1 BrainCheck, Inc. Company Information
  39. 8.7.2 BrainCheck, Inc. Business Overview
  40. 8.7.3 BrainCheck, Inc. Neurocognitive Assessment and Rehabilitation Revenue and Gross Margin (2021-2026)
  41. 8.7.4 BrainCheck, Inc. Neurocognitive Assessment and Rehabilitation Product Portfolio
  42. 8.7.5 BrainCheck, Inc. Recent Developments
  43. 8.8 Constant Therapy Health
  44. 8.8.1 Constant Therapy Health Company Information
  45. 8.8.2 Constant Therapy Health Business Overview
  46. 8.8.3 Constant Therapy Health Neurocognitive Assessment and Rehabilitation Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Constant Therapy Health Neurocognitive Assessment and Rehabilitation Product Portfolio
  48. 8.8.5 Constant Therapy Health Recent Developments
  49. 8.9 NeuronUP SL
  50. 8.9.1 NeuronUP SL Company Information
  51. 8.9.2 NeuronUP SL Business Overview
  52. 8.9.3 NeuronUP SL Neurocognitive Assessment and Rehabilitation Revenue and Gross Margin (2021-2026)
  53. 8.9.4 NeuronUP SL Neurocognitive Assessment and Rehabilitation Product Portfolio
  54. 8.9.5 NeuronUP SL Recent Developments
  55. 8.10 SCHUHFRIED GmbH
  56. 8.10.1 SCHUHFRIED GmbH Company Information
  57. 8.10.2 SCHUHFRIED GmbH Business Overview
  58. 8.10.3 SCHUHFRIED GmbH Neurocognitive Assessment and Rehabilitation Revenue and Gross Margin (2021-2026)
  59. 8.10.4 SCHUHFRIED GmbH Neurocognitive Assessment and Rehabilitation Product Portfolio
  60. 8.10.5 SCHUHFRIED GmbH Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst